Aortic Valve Replacement Devices Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The global aortic valve replacement devices market represents a major segment within the broader cardiovascular medical device industry, valued at approximately $7.69 billion in 2025. The market spans three primary product categories: surgical mechanical valves, bioprosthetic (tissue) valves, and transcatheter aortic valve replacement (TAVR) systems. The transcatheter segment alone was valued at approximately $5.3 billion in 2025, reflecting its dominant share of the overall market.

• •Market valued at approximately $7.69 billion in 2025, with projections to reach roughly $12.8 billion by 2030 at a compound annual growth rate of approximately 9.86%
• •Transcatheter aortic valve replacement (TAVR/TAVI) represents the largest and fastest-growing segment, valued at approximately $5.3 billion in 2025
• •The broader aortic valve market, including repair and reconstruction devices, is estimated at a higher range reflecting differing scope across research firms

The principal driver of market expansion is the rising global prevalence of aortic stenosis, a condition strongly correlated with aging populations. According to epidemiological data, aortic stenosis affects approximately 2-7% of adults over 65 and over 13% of those over 75, creating a large and expanding patient pool requiring intervention. Technological advancements in TAVR systems, including the development of next-generation devices suitable for low-risk patients, have broadened the treatable population beyond high-risk and inoperable patients.

• •Rising global geriatric population is increasing incidence of degenerative aortic valve disease, the primary driver of demand for replacement devices
• •Expanding clinical evidence supporting TAVR use in low-risk patient populations, significantly widening the addressable market beyond inoperable and high-risk patients
• •Favorable regulatory approvals and increasing procedural adoption in emerging markets as healthcare infrastructure and reimbursement frameworks improve

The market is segmented by product type into mechanical valves, bioprosthetic valves, and transcatheter heart valves, with TAVR devices representing the dominant and fastest-growing category. North America holds the largest market share due to high healthcare expenditure, favorable reimbursement policies, and early adoption of advanced technologies, followed by Europe. The Asia-Pacific region is the fastest-growing market segment, driven by rising cardiovascular disease burden, improving healthcare access, and increasing medical tourism.

• •TAVR devices dominate the market, with the transcatheter segment projected to grow at a compound annual rate of approximately 11.7% through 2035
• •North America leads in market share, supported by advanced healthcare infrastructure, favorable reimbursement, and high procedural adoption rates
• •Asia-Pacific is the fastest-growing regional market, driven by rising disease prevalence, economic development, and expanding healthcare access

What are the recent trends and outlook?

The market outlook is characterized by continued rapid growth in transcatheter procedures, ongoing innovation in valve design to improve durability and reduce complications, and expansion into new patient risk categories. Emerging trends include the development of transcatheter mitral and tricuspid valve therapies, increasing adoption of minimally invasive surgical approaches, and the integration of digital technologies in valve selection and procedural planning. The market is expected to maintain a compound annual growth rate of approximately 9-11% through 2030, supported by aging demographics and sustained clinical innovation.

• •TAVR technology is expected to expand into broader patient populations, including those at low surgical risk, driving continued market growth
• •Emerging markets in Asia-Pacific, Latin America, and the Middle East are projected to see accelerated adoption as healthcare access and reimbursement improve
• •Technological innovation in valve durability, minimally invasive delivery systems, and digital procedural planning tools is expected to intensify competitive dynamics